Felzartamab vs HLX15
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Felzartamab
Developed by Biogen and partners
NCT03952091 · Phase 3 · completed
This was a large (n=289), randomized, active-controlled Phase 3 trial using a well-accepted hard clinical endpoint (progression-free survival), and the drug combination showed a statistically significant improvement over the active comparator. However, the trial was conducted completely open-label with no blinding of patients or investigators, which limits confidence in the result despite its objective endpoint and statistical significance.
Reported efficacy
Progression-free survival (PFS) (18.4 months(Active) 30.7 months(experimental)): Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) (met)
Result source: NCT03952091
HLX15
Developed by Dr. Reddy's Laboratories under a licence from Shanghai Henlius Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07477587 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Felzartamab | HLX15 |
|---|---|---|
| PFS, median | —Not posted · NCT03952091 | —Trial running · NCT06895512 |
| OS, median | —Not posted · NCT03952091 | —Trial running · NCT06895512 |
| ORR | —Not posted · NCT03952091 | —Trial running · NCT06895512 |
| VGPR or better | —Not posted · NCT03952091 | —Trial running · NCT06895512 |
| MRD negativity | —Not posted · NCT03952091 | —Trial running · NCT06895512 |
PFS, median
- Felzartamab
- —Not posted · NCT03952091
- HLX15
- —Trial running · NCT06895512
OS, median
- Felzartamab
- —Not posted · NCT03952091
- HLX15
- —Trial running · NCT06895512
ORR
- Felzartamab
- —Not posted · NCT03952091
- HLX15
- —Trial running · NCT06895512
VGPR or better
- Felzartamab
- —Not posted · NCT03952091
- HLX15
- —Trial running · NCT06895512
MRD negativity
- Felzartamab
- —Not posted · NCT03952091
- HLX15
- —Trial running · NCT06895512
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HLX15: no structured comparison results are available for Multiple Myeloma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Felzartamab's landscape · HLX15's landscape